로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Cell > Integrin alpha V beta 6 > CHEK-ATP125

HEK293/Human Integrin alpha V beta 6 Stable Cell Line

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The HEK293/Human Integrin alpha V beta 6 Stable Cell Line was engineered to express the receptors full length human Integrin alpha V (Gene ID: 3685) and Integrin beta 6 (Gene ID: 3694), used to mimic cancer target cells. Surface expression of human Integrin alpha V beta 6 was confirmed by flow cytometry.
  • Application

    • Useful for cell-based Integrin alpha V beta 6 binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin (20 μg/mL)
  • Culture Medium
    DMEM + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 Integrin alpha V beta 6 FACS

Expression analysis of human Integrin alpha V on HEK293/Human Integrin alpha V beta 6 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human Integrin alpha V beta 6 Stable Cell Line or negative control cell using anti-human Integrin alpha V antibody followed by staining with FITC anti-mouse IgG Antibody.

 Integrin alpha V beta 6 FACS

Expression analysis of human Integrin beta 6 on HEK293/Human Integrin alpha V beta 6 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human Integrin alpha V beta 6 Stable Cell Line or negative control cell using anti-human Integrin beta 6 antibody followed by staining with PE anti-human IgG Fc Antibody.

Please contact us if you are interested in related cell pool service.

  • Background
    Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 5,250,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:6 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop